CliffBio
small molecule

BIJUVA

ESTRADIOL; PROGESTERONE

Loss of exclusivityNovember 2032latest FDA-listed patent expiry
CompanyMayne Pharma →See this company's full patent-cliff portfolio

Drug detail

Brand nameBIJUVA
Active ingredientESTRADIOL; PROGESTERONE
Strength1MG;100MG
Dosage formCAPSULE
RouteORAL
ModalitySmall molecule
FDA approvalOctober 2018
Marketing statusRX

Listed patents

PatentExpiresType
10206932November 2032use U-2439
8846649November 2032product
8846648November 2032use U-2439
9114146November 2032product
9114145November 2032use U-2439
10675288November 2032use U-2439
9301920November 2032product
11033626November 2032product
9006222November 2032product
10806740November 2032product
11103513November 2032use U-2439
11793819November 2032use U-2439
8993548November 2032product
8987237November 2032product
11529360November 2032product
8993549November 2032product
10639375November 2032product
8633178November 2032product
10052386November 2032product
11865179November 2032substance, product
11110099November 2032product
11103516November 2032product

More from Mayne Pharma

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

BIJUVA patent cliff — loss of exclusivity November 2032 | CliffBio